{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:59:41Z","timestamp":1776722381399,"version":"3.51.2"},"reference-count":13,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Otolaryngology - Head &amp; Neck Surgery"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p> Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to assess its effectiveness and efficacy in a real-world setting. This study aims to assess how clinical outcomes of biologic therapy in real-world application (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness gap. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> A retrospective study evaluating disease specific sinonasal outcomes routinely collected for clinical care. This study included patients who were evaluated for coverage of dupilumab at a tertiary care rhinology clinic for the treatment of CRSwNP in the first year since dupilumab was approved in Canada for this indication. Sinonasal outcomes were be evaluated by collecting data on the Sino-Nasal Outcome Test (SNOT)-22 questionnaire. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Eighty-five patients were considered for dupilumab therapy during the study period, 49% patients were able to attain coverage for the requested therapy. The mean SNOT-22 score at baseline was 60.56 (SD 21.63). After 16\u00a0weeks of treatment the mean SNOT-22 score decreased by 37 points to 23.36; at 28\u00a0weeks the mean SNOT-22 was 23.47. After 1\u00a0year, the mean SNOT-22 score was 14.37. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Patients treated with dupilumab for CRSwNP at out tertiary rhinology clinic showed substantial clinical symptom improvement that is similar to that observed in prior randomised clinical trials. No serious adverse effects related to dupilumab were reported in this cohort. Long-term follow-up is needed to inform effectiveness analyses beyond the 1\u00a0year clinical trial duration. <\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical Abstract<\/jats:title><jats:p> <\/jats:p><\/jats:sec>","DOI":"10.1186\/s40463-022-00570-0","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T11:02:58Z","timestamp":1650884578000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps"],"prefix":"10.1177","volume":"51","author":[{"given":"Shaun J.","family":"Kilty","sequence":"first","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, The Ottawa Hospital, 737 Parkdale Ave., Room 259, K1Y 1J8, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lasso","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, The Ottawa Hospital, 737 Parkdale Ave., Room 259, K1Y 1J8, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"issue":"2","key":"bibr1-s40463-022-00570-0","first-page":"S99","volume":"40","author":"Desrosiers M","year":"2011","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"bibr2-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1002\/lary.23610"},{"issue":"29","key":"bibr3-s40463-022-00570-0","first-page":"1","volume":"58","author":"Fokkens WJ","year":"2020","journal-title":"Rhinology"},{"key":"bibr4-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26391"},{"key":"bibr5-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"bibr6-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-021-00493-2"},{"key":"bibr7-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"bibr8-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"bibr9-s40463-022-00570-0","unstructured":"CADTH. Canadian Agency for Drugs and Technologies in Health 2020 [Available from: https:\/\/cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0636%20Dupixent%20-%20CDEC%20Final%20%20Recommendation%20April%2024%2C%202020%20for%20posting.pdf."},{"key":"bibr10-s40463-022-00570-0","unstructured":"CADTH. CADTH Reimbursement Recommendation Dupilumab. Canadian Journal of Health Technologies [Internet]. 2021; 1."},{"issue":"1","key":"bibr11-s40463-022-00570-0","first-page":"20","volume":"54","author":"Hopkins C","year":"2016","journal-title":"Public Pract Rhinol"},{"key":"bibr12-s40463-022-00570-0","doi-asserted-by":"publisher","DOI":"10.1007\/s40136-018-0215-3"},{"key":"bibr13-s40463-022-00570-0","unstructured":"World Health Organization. International classification of impairments, disabilities, and handicaps: a manual of classification relating to the consequences of disease. Geneva Albany, N.Y.: World Health Organization; sold by WHO Publications Centre USA; 1980. p. 205."}],"container-title":["Journal of Otolaryngology - Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1186\/s40463-022-00570-0","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40463-022-00570-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1186\/s40463-022-00570-0","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40463-022-00570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1186\/s40463-022-00570-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T06:55:17Z","timestamp":1741676117000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1186\/s40463-022-00570-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1186\/s40463-022-00570-0"],"URL":"https:\/\/doi.org\/10.1186\/s40463-022-00570-0","relation":{},"ISSN":["1916-0216","1916-0216"],"issn-type":[{"value":"1916-0216","type":"print"},{"value":"1916-0216","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17"}}